Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
about
RGS19 upregulates Nm23-H1/2 metastasis suppressors by transcriptional activation via the cAMP/PKA/CREB pathwayFulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.
P2860
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
@en
type
label
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
@en
prefLabel
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
@en
P2860
P1476
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
@en
P2093
Hirotaka Iwase
Yutaka Yamamoto
P2860
P2888
P304
P356
10.1007/S10147-015-0793-8
P577
2015-02-12T00:00:00Z